Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche’s EU Accelerated Assessment Bid For Tumor Agnostic Entrectinib Backfires

Executive Summary

A decision to yoke together two indications in one EU accelerated assessment filing for the anticancer has backfired on Roche and left the product at even more of a disadvantage compared with Bayer’s Vitrakvi in the tumor-agnostic setting.

You may also be interested in...



Bayer's Vitrakvi Is EU’s First Tumor-Agnostic Treatment

The German group's cancer drug is the first to be approved for use in Europe for a wide range of tumors. The principal challenge now is to find eligible patients.

Novartis’s Zolgensma Loses EU Accelerated Assessment

Companies pleased at gaining an EU accelerated assessment for a product should be aware that the agency offers no guarantee that they will get to keep it. Novartis’s Zolgensma is one of seven drugs whose review the EMA has taken off the fast track.

Roche Beats Rivals To Japan Tumor-Agnostic Market With World-First Rozlytrek Nod

Roche’s tumor-agnostic drug receives first approval globally in Japan following an expedited review, giving the Swiss group a lead over its rival in this market. But sales may be limited.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124846

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel